Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.

NCT01796795 is registered in ClinicalTrials.gov with G&E Herbal Biotechnology Co., LTD as lead sponsor.

NCT NCT01796795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01796795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.
Lead sponsor
G&E Herbal Biotechnology Co., LTD
Phase
Phase 2
Overall status
Suspended
Start date
September 30, 2030
Completion date
August 31, 2033
Enrollment
102 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

common wart